BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 35078648)

  • 21. TCGA molecular classification in endometriosis-associated ovarian carcinomas: Novel data on clear cell carcinoma.
    Similä-Maarala J; Soovares P; Pasanen A; Ahvenainen T; Vahteristo P; Bützow R; Lassus H
    Gynecol Oncol; 2022 Jun; 165(3):577-584. PubMed ID: 35370008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The influence of molecular classification in the selection of postoperative adjuvant therapy in endometrial carcinoma].
    Yan XS; Li M; Liang HM; Guo HY; Wu Y; He HJ; Zhang K; Li H
    Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(32):2500-2505. PubMed ID: 36008320
    [No Abstract]   [Full Text] [Related]  

  • 23. Prognostic Impact of Pathologic Features in Molecular Subgroups of Endometrial Carcinoma.
    Ruscelli M; Maloberti T; Corradini AG; Rosini F; Querzoli G; Grillini M; Altimari A; Gruppioni E; Sanza V; Costantino A; Ciudino R; Errani M; Papapietro A; Coluccelli S; Turchetti D; Ferioli M; Giunchi S; Dondi G; Tesei M; Ravegnini G; Abbati F; Rubino D; Zamagni C; D'Angelo E; De Iaco P; Santini D; Ceccarelli C; Perrone AM; Tallini G; de Biase D; De Leo A
    J Pers Med; 2023 Apr; 13(5):. PubMed ID: 37240893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted Molecular Testing in Endometrial Carcinoma: Validation of a Clinically Driven Selective ProMisE Testing Protocol.
    Talhouk A; Jamieson A; Crosbie EJ; Taylor A; Chiu D; Leung S; Grube M; Kommoss S; Gilks CB; McAlpine JN; Singh N
    Int J Gynecol Pathol; 2023 Jul; 42(4):353-363. PubMed ID: 36731023
    [TBL] [Abstract][Full Text] [Related]  

  • 25. p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies.
    Singh N; Piskorz AM; Bosse T; Jimenez-Linan M; Rous B; Brenton JD; Gilks CB; Köbel M
    J Pathol; 2020 Mar; 250(3):336-345. PubMed ID: 31829441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subclonal p53 immunostaining in the diagnosis of endometrial carcinoma molecular subtype.
    Huvila J; Thompson EF; Vanden Broek J; Lum A; Senz J; Leung S; Gilks CB; Köbel M; McAlpine JN; Jamieson A
    Histopathology; 2023 Dec; 83(6):880-890. PubMed ID: 37580913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk stratification and molecular heterogeneity of endometrial cancer and expression profile of TIM-3: A retrospective cohort study.
    Zhang Y; Yang R; Xu C; Zhang Y; Deng M; Wu D; Tang F; Liu X; Han Y; Zhan Y; Miao J
    Gynecol Oncol; 2023 Mar; 170():210-220. PubMed ID: 36709662
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D.
    Timmerman S; Van Rompuy AS; Van Gorp T; Vanden Bempt I; Brems H; Van Nieuwenhuysen E; Han SN; Neven P; Victoor J; Laenen A; Vergote I
    Gynecol Oncol; 2020 Apr; 157(1):245-251. PubMed ID: 31980219
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endometrial carcinoma molecular subtype correlates with the presence of lymph node metastases.
    Jamieson A; Thompson EF; Huvila J; Leung S; Lum A; Morin C; Ennour-Idrissi K; Sebastianelli A; Renaud MC; Gregoire J; Huntsman DG; Gilks CB; Plante M; Grondin K; McAlpine JN
    Gynecol Oncol; 2022 May; 165(2):376-384. PubMed ID: 35504673
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular characterization in the prediction of disease extent in endometrial carcinoma.
    Kolehmainen AM; Pasanen AM; Koivisto-Korander RL; Bützow RC; Loukovaara MJ
    Eur J Obstet Gynecol Reprod Biol; 2021 Jan; 256():478-483. PubMed ID: 33189427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validation of a one-step genomics-based molecular classifier for endometrial carcinoma in a large Chinese population.
    Kang N; Zhang X; Wang Z; Dai Y; Lu S; Su W; Gai F; Zhu C; Shen D; Wang J
    Pathol Res Pract; 2024 Feb; 254():155152. PubMed ID: 38277742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Time to first recurrence, pattern of recurrence, and survival after recurrence in endometrial cancer according to the molecular classification.
    Siegenthaler F; Lindemann K; Epstein E; Rau TT; Nastic D; Ghaderi M; Rydberg F; Mueller MD; Carlson J; Imboden S
    Gynecol Oncol; 2022 May; 165(2):230-238. PubMed ID: 35277281
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential impact of clinicopathological risk factors within the 2 largest ProMisE molecular subgroups of endometrial carcinoma.
    Pasanen A; Loukovaara M; Ahvenainen T; Vahteristo P; Bützow R
    PLoS One; 2021; 16(9):e0253472. PubMed ID: 34473724
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ATM immunohistochemistry as a potential marker for the differential diagnosis of no specific molecular profile subtype and POLE-mutation subtype endometrioid carcinoma.
    Kitazono I; Kobayashi Y; Akahane T; Yamaguchi T; Yanazume S; Nohara S; Sakamoto I; Tabata K; Tasaki T; Kobayashi H; Tanimoto A
    Pathol Res Pract; 2022 Feb; 230():153743. PubMed ID: 34954471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term survival in patients with para-aortic lymph node metastasis with systematic retroperitoneal lymphadenectomy followed by adjuvant chemotherapy in endometrial carcinoma.
    Hiura M; Nogawa T; Matsumoto T; Yokoyama T; Shiroyama Y; Wroblewski J
    Int J Gynecol Cancer; 2010 Aug; 20(6):1000-5. PubMed ID: 20683408
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of
    Beinse G; Rance B; Just PA; Izac B; Letourneur F; Saidu NEB; Chouzenoux S; Nicco C; Goldwasser F; Batteux F; Durdux C; Chapron C; Pasmant E; Leroy K; Alexandre J; Borghese B
    Int J Gynecol Cancer; 2020 May; 30(5):640-647. PubMed ID: 32169874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinico-pathological significance of TCGA classification and SWI/SNF proteins expression in undifferentiated/dedifferentiated endometrial carcinoma: A possible prognostic risk stratification.
    Santoro A; Angelico G; Travaglino A; Raffone A; Arciuolo D; D'Alessandris N; Inzani F; Zannoni GF
    Gynecol Oncol; 2021 May; 161(2):629-635. PubMed ID: 33712277
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Variation in practice in endometrial cancer and potential for improved care and equity through molecular classification.
    Jamieson A; Huvila J; Thompson EF; Leung S; Chiu D; Lum A; McConechy M; Grondin K; Aguirre-Hernandez R; Salvador S; Kean S; Samouelian V; Gougeon F; Azordegan N; Lytwyn A; Parra-Herran C; Offman S; Gotlieb W; Irving J; Kinloch M; Helpman L; Scott SA; Vicus D; Plante M; Huntsman DG; Gilks CB; Talhouk A; McAlpine JN
    Gynecol Oncol; 2022 May; 165(2):201-214. PubMed ID: 35246332
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessing the New 2020 ESGO/ESTRO/ESP Endometrial Cancer Risk Molecular Categorization System for Predicting Survival and Recurrence.
    Ouh YT; Oh Y; Joo J; Woo JH; Han HJ; Cho HW; Lee JK; Chun Y; Lim MN; Hong JH
    Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473326
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mismatch repair protein and MLH1 methylation status as predictors of response to adjuvant therapy in endometrial cancer.
    Loukovaara M; Pasanen A; Bützow R
    Cancer Med; 2021 Feb; 10(3):1034-1042. PubMed ID: 33449452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.